<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; manufacturing</title>
	<atom:link href="http://www.tapanray.in/tag/manufacturing/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Criticality of Bridging the Skill Gap in Today’s Indian Pharma Industry</title>
		<link>http://www.tapanray.in/criticality-of-bridging-the-skill-gap-in-todays-indian-pharma-industry/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=criticality-of-bridging-the-skill-gap-in-todays-indian-pharma-industry</link>
		<comments>http://www.tapanray.in/criticality-of-bridging-the-skill-gap-in-todays-indian-pharma-industry/#comments</comments>
		<pubDate>Sun, 17 Sep 2023 07:14:41 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[gap]]></category>
		<category><![CDATA[increase]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[PMKVY.40.]]></category>
		<category><![CDATA[productivity]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[scheme]]></category>
		<category><![CDATA[shortage]]></category>
		<category><![CDATA[skill]]></category>
		<category><![CDATA[skilled]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[training]]></category>
		<category><![CDATA[workers]]></category>
		<category><![CDATA[workforce]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10820</guid>
		<description><![CDATA[To address the shortage of adequately skilled workers in the country, in 2023, the Government of India released a new version of the national skill development initiative called Pradhan Mantri Kaushal Vikas Yojana 4.0 (PMKVY 4.0). It is touted as a &#8230; <a href="http://www.tapanray.in/criticality-of-bridging-the-skill-gap-in-todays-indian-pharma-industry/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/criticality-of-bridging-the-skill-gap-in-todays-indian-pharma-industry/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Unfettered ‘Access To Drug Innovation’ &#8211; An Oxymoron?</title>
		<link>http://www.tapanray.in/unfettered-access-to-drug-innovation-an-oxymoron/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=unfettered-access-to-drug-innovation-an-oxymoron</link>
		<comments>http://www.tapanray.in/unfettered-access-to-drug-innovation-an-oxymoron/#comments</comments>
		<pubDate>Mon, 06 Sep 2021 00:00:58 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[biosimilars]]></category>
		<category><![CDATA[confidence]]></category>
		<category><![CDATA[Covid19]]></category>
		<category><![CDATA[customer. consumer]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[ecosystem]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[off-patent]]></category>
		<category><![CDATA[Oxymoron]]></category>
		<category><![CDATA[pandemic]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Patients]]></category>
		<category><![CDATA[process]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[property< India]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Standard]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Thicket]]></category>
		<category><![CDATA[undermining]]></category>
		<category><![CDATA[unfettered]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10582</guid>
		<description><![CDATA[The mass paranoia, as it were, over Covid pandemic has now started fading with drug regulators’ ‘emergency approval’ of several Covid -19 vaccines, and its free of cost access to all, generally in most countries. As the endgame of the pandemic, &#8230; <a href="http://www.tapanray.in/unfettered-access-to-drug-innovation-an-oxymoron/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/unfettered-access-to-drug-innovation-an-oxymoron/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Taming Two Critical Covid Uncertainties For Pharma’s Sustainable Growth</title>
		<link>http://www.tapanray.in/taming-two-critical-covid-uncertainties-for-pharmas-sustainable-growth/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=taming-two-critical-covid-uncertainties-for-pharmas-sustainable-growth</link>
		<comments>http://www.tapanray.in/taming-two-critical-covid-uncertainties-for-pharmas-sustainable-growth/#comments</comments>
		<pubDate>Mon, 28 Sep 2020 00:00:56 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Cinvid-19]]></category>
		<category><![CDATA[cold-chain]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[Covid]]></category>
		<category><![CDATA[cure]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Infections]]></category>
		<category><![CDATA[investment]]></category>
		<category><![CDATA[leadership]]></category>
		<category><![CDATA[life]]></category>
		<category><![CDATA[logistics]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[mutating]]></category>
		<category><![CDATA[opportunities]]></category>
		<category><![CDATA[pace-setting]]></category>
		<category><![CDATA[problems]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sustainable]]></category>
		<category><![CDATA[Taming]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[time]]></category>
		<category><![CDATA[uncertainties]]></category>
		<category><![CDATA[vaccines]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10275</guid>
		<description><![CDATA[The reasons behind a great urgency of the Governments, besides high expectations of the general public, to have the ‘ultimate solution’ very soon, against the ongoing pandemic, are understandable. However, various media-hyped narratives on their clinical trials, and timeframe for &#8230; <a href="http://www.tapanray.in/taming-two-critical-covid-uncertainties-for-pharmas-sustainable-growth/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/taming-two-critical-covid-uncertainties-for-pharmas-sustainable-growth/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Time For Predictive Rather Than Reactive Pharma Strategy</title>
		<link>http://www.tapanray.in/time-for-predictive-rather-than-reactive-pharma-strategy/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=time-for-predictive-rather-than-reactive-pharma-strategy</link>
		<comments>http://www.tapanray.in/time-for-predictive-rather-than-reactive-pharma-strategy/#comments</comments>
		<pubDate>Mon, 15 Jun 2020 00:00:38 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Approach]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[care]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[Coronavirus]]></category>
		<category><![CDATA[COVID-19]]></category>
		<category><![CDATA[Digitalization]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[first in class]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[innovative]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[me-too]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[mindset]]></category>
		<category><![CDATA[molecule]]></category>
		<category><![CDATA[pathway]]></category>
		<category><![CDATA[predictive]]></category>
		<category><![CDATA[proactive]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[reactive]]></category>
		<category><![CDATA[safe]]></category>
		<category><![CDATA[sailing]]></category>
		<category><![CDATA[sales]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[supply-chain]]></category>
		<category><![CDATA[system]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[traditional]]></category>
		<category><![CDATA[value-based]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=10126</guid>
		<description><![CDATA[Traditionally, pharmaceutical industry, across the world, is mostly reactive &#8211; rather than proactive or predictive in its strategic approach &#8211; spanning across all its business domains. A large number of pharma players &#8211; both innovators and generic drug makers, formulate &#8230; <a href="http://www.tapanray.in/time-for-predictive-rather-than-reactive-pharma-strategy/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/time-for-predictive-rather-than-reactive-pharma-strategy/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Branding At Tough Times</title>
		<link>http://www.tapanray.in/pharma-branding-at-tough-times/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-branding-at-tough-times</link>
		<comments>http://www.tapanray.in/pharma-branding-at-tough-times/#comments</comments>
		<pubDate>Mon, 18 Nov 2019 00:00:18 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[bias]]></category>
		<category><![CDATA[brand]]></category>
		<category><![CDATA[branding]]></category>
		<category><![CDATA[chain]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[creation]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[disclosure]]></category>
		<category><![CDATA[failures]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[positive]]></category>
		<category><![CDATA[Prime]]></category>
		<category><![CDATA[Prompt]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[stakeholder]]></category>
		<category><![CDATA[strategy]]></category>
		<category><![CDATA[Supply]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[times]]></category>
		<category><![CDATA[Tough]]></category>
		<category><![CDATA[value]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9784</guid>
		<description><![CDATA[“About two-thirds of drug launches don’t meet expectations. Improving that record requires pharmaceutical companies to recognize the world has changed and adjust their marketing accordingly.” This appeared in an article – “The secret of successful drug launches,” published by McKinsey &#38; Company in &#8230; <a href="http://www.tapanray.in/pharma-branding-at-tough-times/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-branding-at-tough-times/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A New Facet of ‘Data Integrity’ With Novel Therapy… And Much Beyond</title>
		<link>http://www.tapanray.in/a-new-facet-of-data-integrity-with-novel-therapy-and-much-beyond/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-new-facet-of-data-integrity-with-novel-therapy-and-much-beyond</link>
		<comments>http://www.tapanray.in/a-new-facet-of-data-integrity-with-novel-therapy-and-much-beyond/#comments</comments>
		<pubDate>Mon, 30 Sep 2019 00:00:52 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[AveXis]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[cGMP]]></category>
		<category><![CDATA[cherry-picking]]></category>
		<category><![CDATA[clinical trial]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[facet]]></category>
		<category><![CDATA[GCP]]></category>
		<category><![CDATA[gene]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Integrity]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[Zolgensma]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9728</guid>
		<description><![CDATA[The peril of breach of data integrity involving a top Indian pharma player, jolted many, probably for the first time, on September 17, 2008. On that day, the USFDA, reportedly, issued two ‘Warning Letters’ and an ‘Import Alert’. These were related to &#8230; <a href="http://www.tapanray.in/a-new-facet-of-data-integrity-with-novel-therapy-and-much-beyond/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-new-facet-of-data-integrity-with-novel-therapy-and-much-beyond/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Stakeholder Sentiment: Back to Square One?</title>
		<link>http://www.tapanray.in/pharma-stakeholder-sentiment-back-to-square-one/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-stakeholder-sentiment-back-to-square-one</link>
		<comments>http://www.tapanray.in/pharma-stakeholder-sentiment-back-to-square-one/#comments</comments>
		<pubDate>Mon, 28 May 2018 00:00:19 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[Bayer]]></category>
		<category><![CDATA[CEO]]></category>
		<category><![CDATA[Change]]></category>
		<category><![CDATA[core]]></category>
		<category><![CDATA[Dekkers]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[discovery]]></category>
		<category><![CDATA[Drucker]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[George]]></category>
		<category><![CDATA[guru]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[Marjin]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[maximizing]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[non-profit]]></category>
		<category><![CDATA[one]]></category>
		<category><![CDATA[Peter]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[profit]]></category>
		<category><![CDATA[purpose]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[sentiment]]></category>
		<category><![CDATA[socializing]]></category>
		<category><![CDATA[square]]></category>
		<category><![CDATA[stakeholder]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[witty]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8965</guid>
		<description><![CDATA[Is it fair to push out the core purpose of an important process, or rather a mission, unfairly? Whether we like it or not, it happened that way, over a period of time. Way back on December 01, 1950, George W. &#8230; <a href="http://www.tapanray.in/pharma-stakeholder-sentiment-back-to-square-one/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-stakeholder-sentiment-back-to-square-one/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Why MNC Pharma Still Moans Over Indian IP Ecosystem?</title>
		<link>http://www.tapanray.in/why-mnc-pharma-still-moans-over-indian-ip-ecosystem/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=why-mnc-pharma-still-moans-over-indian-ip-ecosystem</link>
		<comments>http://www.tapanray.in/why-mnc-pharma-still-moans-over-indian-ip-ecosystem/#comments</comments>
		<pubDate>Mon, 14 May 2018 00:00:03 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[2018]]></category>
		<category><![CDATA[3.d]]></category>
		<category><![CDATA[301]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[Bank]]></category>
		<category><![CDATA[Chamber]]></category>
		<category><![CDATA[Cheaper]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Commerce]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[competition]]></category>
		<category><![CDATA[Compulsory]]></category>
		<category><![CDATA[concerns]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[ecosystem]]></category>
		<category><![CDATA[expensive]]></category>
		<category><![CDATA[Form 27]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Index]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Intellectual]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[License]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[MNC]]></category>
		<category><![CDATA[Moon]]></category>
		<category><![CDATA[multi]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[PhRMA]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Property]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Report]]></category>
		<category><![CDATA[Socioeconomic]]></category>
		<category><![CDATA[Special]]></category>
		<category><![CDATA[TADF]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UN]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USTR]]></category>
		<category><![CDATA[working]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=9004</guid>
		<description><![CDATA[Improving patient access to expensive drugs, paving the way for entry of their cheaper generic equivalents, post patent expiry, and avoiding evergreening, is assuming priority a priority focus area in many countries. The United States is no exception, in this &#8230; <a href="http://www.tapanray.in/why-mnc-pharma-still-moans-over-indian-ip-ecosystem/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/why-mnc-pharma-still-moans-over-indian-ip-ecosystem/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>For Improving Drug Quality in India &#8211; A Bizarre Intent</title>
		<link>http://www.tapanray.in/for-improving-drug-quality-in-india-a-bizarre-intent/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=for-improving-drug-quality-in-india-a-bizarre-intent</link>
		<comments>http://www.tapanray.in/for-improving-drug-quality-in-india-a-bizarre-intent/#comments</comments>
		<pubDate>Sun, 28 Jan 2018 23:43:28 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[ban]]></category>
		<category><![CDATA[bizarre]]></category>
		<category><![CDATA[bulk]]></category>
		<category><![CDATA[CDSCO]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Chinese]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Delhi]]></category>
		<category><![CDATA[DI]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[European]]></category>
		<category><![CDATA[facilities]]></category>
		<category><![CDATA[Fake]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[import]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[inspection]]></category>
		<category><![CDATA[Inspectors]]></category>
		<category><![CDATA[Kerala]]></category>
		<category><![CDATA[Maharashtra]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[Misplaced]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[plants]]></category>
		<category><![CDATA[Priority]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Shortages]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[substandard]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[USFDA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=8778</guid>
		<description><![CDATA[On January 16, 2017, quoting a Government source, a media report revealed, “India&#8217;s drug regulator is looking to inspect US pharmaceutical facilities, making critical medicines so that only high-quality products are imported from them.” This intent follows a similar decision &#8230; <a href="http://www.tapanray.in/for-improving-drug-quality-in-india-a-bizarre-intent/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/for-improving-drug-quality-in-india-a-bizarre-intent/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>PE Investment In Pharma: The Changing Need Of Due Diligence</title>
		<link>http://www.tapanray.in/pe-investment-in-pharma-the-changing-need-of-due-diligence/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pe-investment-in-pharma-the-changing-need-of-due-diligence</link>
		<comments>http://www.tapanray.in/pe-investment-in-pharma-the-changing-need-of-due-diligence/#comments</comments>
		<pubDate>Mon, 02 May 2016 00:00:19 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[cGMP]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[DCGI]]></category>
		<category><![CDATA[Directors]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[due diligence]]></category>
		<category><![CDATA[equity]]></category>
		<category><![CDATA[FSSAI]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[good]]></category>
		<category><![CDATA[governance]]></category>
		<category><![CDATA[Independent]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Indian]]></category>
		<category><![CDATA[investment]]></category>
		<category><![CDATA[Investor]]></category>
		<category><![CDATA[manufacturing]]></category>
		<category><![CDATA[Nutraceuticals]]></category>
		<category><![CDATA[PE]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[private]]></category>
		<category><![CDATA[promoters]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[UCPMP]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=7621</guid>
		<description><![CDATA[From an international perspective, a Bain &#38; Company report of April 2016 highlighted setting a new healthcare M&#38;A record in the year 2015. During this year the total deal value was over 2.5 times higher than the average annual deal value &#8230; <a href="http://www.tapanray.in/pe-investment-in-pharma-the-changing-need-of-due-diligence/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pe-investment-in-pharma-the-changing-need-of-due-diligence/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
